UBS Group
SABSW icon

UBS Group’s SAB Biotherapeutics Warrant SABSW Stock Holding History

UBS Group’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105 Sell
4,186
-2,000
-32% -$69 ﹤0.01% 10113
2025
Q4 		$192 Sell
6,186
-17,228
-74% -$524 ﹤0.01% 10118
2025
Q3 		$539 Buy
+23,414
New +$782 ﹤0.01% 9635
2025
Q1 		– Sell
-1,633
Closed -$122 – 10655
2024
Q4 		$122 Buy
+1,633
New +$98 ﹤0.01% 9630
2024
Q3 		– Sell
-56
Closed -$3 – 9989
2024
Q2 		$3 Buy
+56
New +$2 ﹤0.01% 9412
2024
Q1 		– Sell
-29,080
Closed -$872 – 9925
2023
Q4 		$872 Buy
+29,080
New +$1.75K ﹤0.01% 8489
2023
Q3 		– Sell
-100
Closed -$10 – 9893
2023
Q2 		$10 Buy
+100
New +$10 ﹤0.01% 8736
2022
Q4 		– Sell
-5,606
Closed – – 11082
2022
Q3 		$0 Buy
+5,606
New +$669 ﹤0.01% 10840
2022
Q1 		– Sell
-2,888
Closed -$5K – 10812
2021
Q4 		$5K Sell
2,888
-202
-7% -$371 ﹤0.01% 9415
2021
Q3 		$3K Buy
3,090
+939
+44% +$671 ﹤0.01% 8833
2021
Q2 		$2K Sell
2,151
-1,378
-39% -$1K ﹤0.01% 8972
2021
Q1 		$2K Buy
+3,529
New +$3.67K ﹤0.01% 8637

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group's SABSW Position: Q1 2026 in Review

UBS Group reduced its SAB Biotherapeutics Warrant (SABSW) stake by 32% in Q1 2026, selling an estimated $69 and leaving 4,186 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #10113.

UBS Group first reported a position in SABSW in Q1 2021 and has held it in 12 quarters since. The position peaked at $5K in Q4 2021. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

  • UBS Group held 4,186 shares of SAB Biotherapeutics Warrant worth $105 as of Q1 2026.
  • UBS Group sold 2,000 SAB Biotherapeutics Warrant shares in Q1 2026, an estimated $69.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10113 holding.
  • UBS Group first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 12 quarters since.
  • UBS Group's SAB Biotherapeutics Warrant position peaked at $5K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.